A randomized controlled trial comparing powdery sublingual misoprostol and sublingual misoprostol tablet for management of embryonic death or anembryonic pregnancy

作者：Saichua Chatawan; Phupong Vorapong^*

来源：Archives of Gynecology and Obstetrics, 2009, 280(3): 431-435.

DOI：10.1007/s00404-009-0947-x

• Misoprostol
• Sublingual
• Powder
• Embryonic death
• Anembryonic pregnancy

To compare complete abortion rate, duration of abortion, and side effects between 600 mu g powdery sublingual misoprostol and 600 mu g sublingual misoprostol tablet for management of embryonic death or anembryonic pregnancy.
Fifty-four pregnant women up to 13 weeks of gestation diagnosed with embryonic death or anembryonic pregnancy were randomized to receive 600 mu g powdery sublingual misoprostol or 600 mu g sublingual misoprostol tablet. Complete abortion was evaluated by transvaginal ultrasound at 48 h.
Twenty-six patients received 600 mu g powdery sublingual misoprostol and 28 patients received 600 mu g sublingual misoprostol tablet. Complete abortion rate was 34.6% in powdery sublingual misoprostol group and 32.1% in sublingual misoprostol tablet group (P = 0.847). Duration of abortion in powdery sublingual misoprostol group and sublingual misoprostol tablet group was similar (34.7 +/- A 18.8 vs. 36.9 +/- A 17.8 h, respectively, P = 0.656). There was no significant difference in the side effects between both groups.
Single dose of 600 mu g of powdery sublingual misoprostol does not improve its efficacy for management of embryonic death or anembryonic pregnancy when compared to sublingual misoprostol tablet.

• 出版日期2009-9